Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-896-9100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$500,000.00
Profitability
Miscellaneous
Employees29
Next Earnings Date8/13/2019 (Estimated)
OptionableOptionable
Celsion (NASDAQ:CLSN) Frequently Asked Questions
What is Celsion's stock symbol?
Celsion trades on the NASDAQ under the ticker symbol "CLSN."
When did Celsion's stock split? How did Celsion's stock split work?
Celsion shares reverse split on the morning of Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.
How were Celsion's earnings last quarter?
Celsion Co. (NASDAQ:CLSN) released its quarterly earnings data on Wednesday, May, 15th. The biotechnology company reported ($0.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.01. The biotechnology company had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative return on equity of 65.35% and a negative net margin of 1,954.60%. View Celsion's Earnings History.
When is Celsion's next earnings date?
What price target have analysts set for CLSN?
2 analysts have issued 12 month price targets for Celsion's stock. Their predictions range from $9.00 to $9.00. On average, they anticipate Celsion's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 339.0% from the stock's current price. View Analyst Price Targets for Celsion.
What is the consensus analysts' recommendation for Celsion?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celsion.
Has Celsion been receiving favorable news coverage?
Media headlines about CLSN stock have been trending neutral on Friday, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Celsion earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Celsion's key competitors?
Some companies that are related to Celsion include Intec Pharma (NTEC), Menlo Therapeutics (MNLO), REDHILL BIOPHAR/S (RDHL), Newron Pharmaceuticals (NWPHF), Cue Biopharma (CUE), Strongbridge Biopharma (SBBP), Checkpoint Therapeutics (CKPT), LifeVantage (LFVN), Trevi Therapeutics (TRVI), Sol Gel Technologies (SLGL), Harrow Health (HROW), Sesen Bio (SESN), XOMA (XOMA), Mustang Bio (MBIO) and Tyme Technologies (TYME).
What other stocks do shareholders of Celsion own?
Who are Celsion's key executives?
Celsion's management team includes the folowing people:
- Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 68)
- Mr. Jeffrey W. Church CPA, CPA, CFO, Exec. VP & Corp. Sec. (Age 62)
- Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 59)
- Dr. Nicholas Borys, Exec. VP & Chief Medical Officer (Age 60)
- Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 61)
Who are Celsion's major shareholders?
Celsion's stock is owned by a number of of institutional and retail investors. Top institutional investors include Northern Trust Corp (0.18%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz, Michael H Tardugno and Robert W Hooper. View Institutional Ownership Trends for Celsion.
Which institutional investors are buying Celsion stock?
CLSN stock was purchased by a variety of institutional investors in the last quarter, including Northern Trust Corp. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Frederick J Fritz, Michael H Tardugno and Robert W Hooper. View Insider Buying and Selling for Celsion.
How do I buy shares of Celsion?
Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celsion's stock price today?
One share of CLSN stock can currently be purchased for approximately $2.05.
How big of a company is Celsion?
Celsion has a market capitalization of $41.99 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-11,880,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Celsion employs 29 workers across the globe.
What is Celsion's official website?
How can I contact Celsion?
Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]
MarketBeat Community Rating for Celsion (NASDAQ CLSN)
MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote "Outperform" if you believe CLSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
